Swiss-based Ferring Pharmaceuticals has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for REKOVELLE (follitropin delta).

The European Commission will grant marketing authorisation for REKOVELLE to use in controlled ovarian stimulation for the development of multiple follicles in women who are undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Later on national authorities in Norway and Iceland will authorise REKOVELLE.

Upon securing approval, an individualised dosing regimen will be used to administer REKOVELLE according to a woman’s serum anti-Müllerian hormone (AMH) level and her body weight.

"If approved, this would be the first pairing of a drug with a companion diagnostic for individualised dosing in reproductive medicine."

AMH is a biomarker used to assess ovarian reserve, which can help to predict ovarian response to controlled ovarian stimulation.

It will also identify patients who may be at higher risk of experiencing reduced efficacy or increased safety concerns.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Ferring Pharmaceuticals chief scientific officer and executive vice-president Dr Per Falk said: “The individualised dosing regimen for REKOVELLE aims to further enrich the personalised care that fertility specialists offer their patients.

“If approved, this would be the first pairing of a drug with a companion diagnostic for individualised dosing in reproductive medicine.”

The positive opinion by CHMP is based on a clinical development programme, including the Phase III Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World (ESTHER) trials that involved 1,326 patients in 11 countries, and more than 2,000 cycles of controlled ovarian stimulation.

The Phase III clinical trials also demonstrated no increased immunogenicity risk and a good safety profile for REKOVELLE.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact